Moderna's Ebola Filing, GSK Truce and a Sharper R&D Budget Set the Table for November 12

Moderna has circled November 12, 2026 on the calendar for an analyst day, with the proceedings due to get underway at 9 a.m. US Eastern time. The event lands just days after a quarterly report that reshaped the company's financial outlook — and against a backdrop of clinical and legal developments that give management plenty to talk about.

A Profit, and a Much Bigger Cash Pile

Third-quarter 2026 revenue came in at $1.3 billion, accompanied by net income of $0.2 billion under GAAP and diluted earnings per share of $0.38. The company also raised its full-year revenue growth guidance to a range of 15% to 25%, up from a prior forecast of as much as 10%.

Operating expenses are now expected to run roughly $0.2 billion lower than previously guided. Research spending, specifically, has been trimmed to about $2.7 billion. The most dramatic revision concerns year-end cash, cash equivalents and investments: Moderna now projects $8.1 billion to $8.3 billion, far above the $4.7 billion to $5.2 billion range it had previously outlined.

That is a striking upgrade to the balance sheet story, and it gives the research narrative a concrete financial anchor. The question investors will want answered is whether the money is being deployed in a way that turns development programmes into verifiable progress.

Ebola Candidate Moves Toward an Efficacy Trial

On November 4, the World Health Organization said Moderna's mRNA-1469 vaccine candidate against the Bundibugyo Ebola virus should be included in the Tumaini study. The recommendation points toward a Phase 2/3 efficacy trial in the Democratic Republic of Congo — the step where a development candidate either earns commercial weight or doesn't. For now, the project's value rests on whether its medical benefit can be demonstrated in the planned investigation.

ASH Slot for mRNA-2808

The same day brought word that early clinical data from the ongoing Phase 1/2 study of mRNA-2808 have been selected for an oral presentation at the 2026 annual meeting of the American Society of Hematology. It is a reminder that Moderna's pipeline extends beyond infectious disease.

GSK Settlement Clears the Legal Deck

A second building block came on October 28, when Moderna and GSK agreed to settle all pending disputes in the US and Europe. The two companies also granted each other patent licences in the field of infectious diseases, with no payments due under those licences. The combination — mutual access without royalties changing hands — makes the truce a meaningful part of the investment case, setting the legal framework while leaving clinical success tied to the individual research programmes.

What to Watch on November 12

The analyst day will be the proving ground where financial priorities meet development goals. A smaller research budget reads as efficiency only if the key programmes keep hitting their next milestones. That is the yardstick against which the friendlier market valuation — and the raised price targets that followed the quarterly numbers — ought to be measured.